Multi-cancer early detection (MCED)

Analytical & testing servicesCategory
By quotePrice
Sourced to orderFulfilment
Procurement categoryItem type

Multi-cancer early detection (MCED) screens asymptomatic, average-risk individuals from a single blood draw for molecular signals shared across dozens of cancer types — a population-screening scenario distinct from companion-therapy diagnostics. The technology base is circulating-DNA, methylation-pattern and protein-signal analysis. Laboratory services and screening programmes based on multi-cancer panels are procured.

Procurement category: analytics & testing. Bioecon selects providers and organises the work in this category to the customer's brief. Catalogue-level entry: the specific manufacturer, configuration and specification are determined at the enquiry stage. Price — on request.

Category sluganalytical-testing
Clusterdiagnostics-medtech
Articlemulti-cancer-early-detection
Identifierbio.svc.multi-cancer-early-detection.analytical-testing
Request a quote →Technology analysis → Open in the shop →

Every item is a procurement category, not a named manufacturer's product. Bioecon is a single seller and holds no stock: supplier selection, configuration and specification are settled at enquiry, and the price is by quote.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.